Results 91 to 100 of about 5,729,125 (133)

Identification of therapeutic targets and prognostic biomarkers in the Siglec family of genes in tumor immune microenvironment of sarcoma

Scientific Reports
Sarcomas (SARC) are a highly heterogeneous cancer type that is prone to recurrence and metastasis. Numerous studies have confirmed that Siglecs are involved in immune signaling and play a key role in regulating immune responses in inflammatory diseases ...
Lili Qi, Kuiying Jiang, Fei-fei Zhao, Ping Ren, Ling Wang   +4 more
doaj   +1 more source

IL-4-STAT6-induced high Siglec-G/10 expression aggravates the severe immune suppressive tumor microenvironment and impedes the efficacy of immunotherapy in head and neck squamous cell carcinoma

Journal for ImmunoTherapy of Cancer
Background Immune checkpoint blockade therapy has shown limited efficacy in head and neck squamous cell carcinoma (HNSCC). Sialic acid binding immunoglobulin-like lectin (Siglec)-15 has been identified as a novel immune evasion biomarker, while the role ...
Ming Yan, Wenyi Yang, Zhaoyang Guo, Houyu Ju, Yusheng Lu, Yifan Fei, Yuanchen Yin, Guoxin Ren, Chaofeng Han, Jingzhou Hu   +9 more
doaj   +1 more source

GW4869 Depletes Macrophages and Increases Number of Extracellular Vesicles in Murine Peritoneal Cavity Fluid

Journal of Extracellular Biology, Volume 5, Issue 9, September 2026.
ABSTRACT Pharmacological strategies to modulate extracellular vesicle (EV) release in vivo are gaining traction, yet their broader effects on local immune microenvironments remain unclear. In this study, we assessed how repeated intraperitoneal (i.p.) dosing of the neutral sphingomyelinase inhibitor GW4869 reshapes the peritoneal cavity.
Johann Mar Gudbergsson, Pedro Henrique Gobira, Rodrigo Grassi‐Oliveira, Anders Etzerodt   +3 more
wiley   +1 more source

Sialic acid cis-ligand dynamics modulate Siglec-7 and -9 function and affect Siglec-7/9 co-blockade to potentiate natural killer cell anti-tumor activity

OncoImmunology
The glyco-immune checkpoints Siglec-7 and Siglec-9 have received considerable interest as targets for cancer immunotherapy. How Siglec-7/9-sialic acid cis-interactions on immune cells influence trans-signaling induced by tumor cells and whether Siglec-7 ...
Jesper van Eck van der Sluijs, Anne H. C. Valk, Eline J. H. van Houtum, Esther D. Kers-Rebel, Maaike Looman, Willemijn Hobo, Anna E. Marneth, Harry Dolstra, Lune van den Boogaard, Christian Büll, Lenneke A. M. Cornelissen, Gosse J. Adema   +11 more
doaj   +1 more source

Protein Posttranslational Modifications in Immunity: Molecular Mechanisms and Therapeutic Targets

MedComm, Volume 7, Issue 9, September 2026.
Protein posttranslational modifications, including phosphorylation, ubiquitination, SUMOylation, acetylation, methylation, glycosylation, and other new types, dynamically regulate antigen presentation and recognition, immune signal transduction, antibody production and class switching, immune contraction, immune memory establishment, as well as immune ...
Yuxing Yao, Jinxiu Qian, Qiqiong Liu, Wanting Ye, Ying Xing, Xiuyun Bai, Rongjun Deng, Jue Yang, Cheng Lu, Cheng Xiao, Yuanyan Liu   +10 more
wiley   +1 more source

CA72-4 derived from synovial cells inhibits monosodium urate-induced macrophage M1 polarization by activating the TIGIT/SHP-1 axis through binding to Siglec-15

Autoimmunity
Excessive M1 polarization of macrophages is a key driver of inflammatory processes in gout, while the regulatory mechanisms involved remain unclear. Herein, the role of carbohydrate antigen 72-4 (CA72-4), derived from human synovial cells (HFLS), in ...
Honglei Hu, Xuefeng Bai, Lingyue Zhang, Hongmei Zhang, Qiang You, Shujuan Wang, Xueshan Bai   +6 more
doaj   +1 more source

Immune Checkpoint Inhibitors in Cancer Therapy: Clinical Landscape, Resistance Mechanisms, and Therapeutic Innovations

MedComm – Oncology, Volume 5, Issue 3, September 2026.
The up‐to‐date clinical progress of immune checkpoint inhibitor (ICI) therapy in solid tumors, specifically the combinational regimens between ICIs and other treatment strategies, the mechanisms underlying primary and acquired resistance, and mechanism‐matched strategies to improve clinical outcomes are synthesized in this review.
Qiongyu Zhang, Zhi Qin, Caijuan Guo
wiley   +1 more source

Siglec-1 RNAi reduces VCC volumes in HIV-1 NLUdel-infected MDMs.

, 2017
(A) MDMs were infected with VSV-G pseudotyped NLUdel. On the following day, MDMs were transfected with 60 nM scrambled, Siglec-1 or tetherin siRNA. At day 10 post-infection, MDMs were washed, fixed with 4% PFA and immunostained for p24 (green), Siglec-1 (
Sarah Takushi (3699919), Neal Beeman (3699922), Jason E. Hammonds (3699916), Lingmei Ding (324106), Jaang-Jiun Wang (253626), Gregory B. Melikyan (137795), Paul Spearman (156002), Ashwanth C. Francis (2836463)   +7 more
core   +1 more source

Cancer Vaccine Development: Toward Artificial Intelligence‐Assisted Personalized Cell Membrane Nanovaccine

Small, Volume 22, Issue 49, 1 September 2026.
Cancer nanovaccines have emerged as promising alternatives to conventional cancer vaccines, which have shown limited clinical efficacy. In particular, cell membrane nanoparticle‐based nanovaccines can offer high biocompatibility and immunogenicity while preserving tumor antigens, including antigen repertoires.
Munsik Kim, Ilkoo Noh
wiley   +1 more source

A Sulfonamide Intermediate Elicits Therapeutic Effect Against Sepsis by Enhancing Neutrophil Maturation

Journal of Cellular and Molecular Medicine, Volume 30, Issue 17, September 2026.
ABSTRACT Sepsis, a life‐threatening condition characterized by systemic inflammation and immune dysregulation, remains a major cause of mortality worldwide. Here, we identify a synthetic sulfonamide intermediate, 1‐[5‐(2‐fluorophenyl)furan‐2‐yl]‐N‐(4‐methylbenzyl)methanamine (FMM), as a host‐directed therapeutic candidate that enhances neutrophil ...
Ji Ye Park, Yu Sun Jeong, Myeongsu Shin, Jiwoo Choi, Jiwon Shin, Leezhi Kwon, Kanghyun Lyu, Hwangi Jo, Youngjoo Byun, JaeHyung Koo, Yoe‐Sik Bae   +10 more
wiley   +1 more source